Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Sees Premarin Emerging Unscathed From WHI; Prempro Rxs Down 25%

Executive Summary

Wyeth expects the Premarin brand to hold up through the negative attention surrounding hormone replacement therapy and Prempro
Advertisement

Related Content

Prempro, Premarin Not Indicated For Coronary Heart Disease – Revised Label
Prempro, Premarin Not Indicated For Coronary Heart Disease – Revised Label
Wyeth Prempro Updated Label Submission Soon; HHS To Discuss WHI Results
Wyeth Prempro Updated Label Submission Soon; HHS To Discuss WHI Results
WHI Prempro Study Shows Need For Rx Marketing Restraint – Kessler On NPR
WHI Prempro Study Shows Need For Rx Marketing Restraint – Kessler On NPR
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review
Wyeth Premarin Plan For 2002: Stabilize Rxs Ahead Of Low-Dose Launch
Advertisement
UsernamePublicRestriction

Register

PS040247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel